DRTS

MKT CAP:$718M

Alpha Tau Medical Ltd.

Market Cap

$718M

Healthcare·Biotechnology·🇮🇱 Israel·NASDAQ

Healthcare·Biotechnology·🇮🇱·NASDAQ

Stock Price

$7.90+$3.07 (+63.56%)

Apr 21, 2026

Company Details

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the U...

CEO

Uzi Sofer

IPO Date

Mar 8, 2021

Website

www.alphatau.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$43M

EPS (Diluted)

-$0.53

Free Cash Flow

-$33M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 9, 2026

$0EPS -$0.53

Q4 2025

Mar 9, 2026

$0EPS -$0.14

Q3 2025

Sep 30, 2025

$0EPS -$0.14

Q2 2025

Aug 11, 2025

$0EPS -$0.13

Q1 2025

Mar 31, 2025

$0EPS -$0.12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$231.0K	-$9M
Q2 22	$0	$0	-$8M
Q3 22	$0	$0	-$7M
Q4 22	$0	-$979.0K	-$8M
Q1 23	$0	$0	-$9M
Q2 23	$0	-$512.0K	-$8M
Q3 23	$0	$0	-$9M
Q4 23	$0	-$1M	-$10M
Q1 24	$0	$0	-$8M
Q2 24	$0	$0	-$9M
Q3 24	$0	$0	-$8M
Q4 24	$0	$0	-$10M
Q1 25	$0	$0	-$9M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	$49M
Q4 25	$0	$0	-$13M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$7M	-$7M
Q2 22	$0	$0
Q3 22	$0	$0
Q4 22	$0	$0
Q1 23	$0	$0
Q2 23	$0	$0
Q3 23	$0	$0
Q4 23	$0	$0
Q1 24	$0	$0
Q2 24	$0	$0
Q3 24	$0	$0
Q4 24	$0	$0
Q1 25	$0	$0
Q2 25	$0	$0
Q3 25	$0	$0
Q4 25	-$27M	-$33M

Capital Expenditures

Quarter	CapEx
Q1 22	$298.0K
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$6M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+360.0%
Q2 22	—	+192.9%
Q3 22	—	+111.6%
Q4 22	—	+119.7%
Q1 23	—	-1.6%
Q2 23	—	+1.9%
Q3 23	—	+21.3%
Q4 23	—	+24.5%
Q1 24	—	-2.5%
Q2 24	—	+10.8%
Q3 24	—	-7.1%
Q4 24	—	+3.3%
Q1 25	—	+10.5%
Q2 25	—	+6.6%
Q3 25	—	-686.8%
Q4 25	—	+22.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q3 24	$0	—
Q4 24	$0	—
Q1 25	$0	—
Q2 25	$0	—
Q3 25	$0	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$5M	$3M	$208.0K
Q2 22	$5M	$2M	$121.0K
Q3 22	$5M	$2M	$248.0K
Q4 22	$5M	$2M	$397.0K
Q1 23	$6M	$2M	$400.0K
Q2 23	$6M	$2M	$520.0K
Q3 23	$7M	$2M	$552.0K
Q4 23	$7M	$2M	$452.0K
Q1 24	$6M	$1M	$533.0K
Q2 24	$7M	$2M	$600.0K
Q3 24	$6M	$2M	$529.0K
Q4 24	$8M	$2M	$687.0K
Q1 25	$7M	$2M	$459.0K
Q2 25	$7M	$2M	$459.0K
Q3 25	$8M	$2M	$490.0K
Q4 25	$10M	$3M	$452.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$98M	$8M	$106M
Q2 22	$12M	$100M	$112M
Q3 22	$6M	$102M	$108M
Q4 22	$6M	$99M	$105M
Q1 23	$899.0K	$99M	$100M
Q2 23	$855.0K	$93M	$94M
Q3 23	$82.0K	$87M	$87M
Q4 23	$16M	$69M	$85M
Q1 24	$10M	$70M	$81M
Q2 24	$3M	$68M	$71M
Q3 24	$6M	$60M	$65M
Q4 24	$14M	$46M	$60M
Q1 25	$5M	$47M	$52M
Q2 25	$12M	$68M	$80M
Q3 25	$3M	$69M	$72M
Q4 25	$16M	$61M	$77M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	48M	-29.7%	+12.5%
Q2 22	68M	+44.0%	+1.2%
Q3 22	69M	+0.5%	+1.7%
Q4 22	69M	+0.4%	+2.2%
Q1 23	69M	+0.1%	+45.7%
Q2 23	69M	+0.2%	+1.3%
Q3 23	69M	+0.2%	+1.0%
Q4 23	70M	+0.3%	+0.8%
Q1 24	70M	+0.1%	+0.7%
Q2 24	70M	+0.2%	+0.8%
Q3 24	70M	+0.0%	+0.6%
Q4 24	70M	+0.3%	+0.6%
Q1 25	70M	+0.5%	+1.1%
Q2 25	80M	+14.1%	+15.0%
Q3 25	85M	+6.1%	+22.0%
Q4 25	86M	+0.5%	+22.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	88
Q2 22	$0	88
Q3 22	$0	88
Q4 22	$0	100
Q1 23	$0	100
Q2 23	$0	100
Q3 23	$0	100
Q4 23	$0	121
Q1 24	$0	121
Q2 24	$0	121
Q3 24	$0	121
Q4 24	$0	130
Q1 25	$0	130
Q2 25	$0	130
Q3 25	$0	130
Q4 25	$0	130

Revenue / Employee